Is Kaleido Biosciences Inc (KLDO) Stock a Good Buy in Biotechnology

Monday, January 27, 2020 12:24 PM | InvestorsObserver Analysts

Kaleido Biosciences Inc (KLDO) is near the top in its industry group according to InvestorsObserver. KLDO gets an overall rating of 49. That means it scores higher than 49 percent of stocks. Kaleido Biosciences Inc gets a 52 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Kaleido Biosciences Inc (KLDO) Stock.

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 49 means the stock is more attractive than 49 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Kaleido Biosciences Inc Stock Today?

Kaleido Biosciences Inc (KLDO) stock is up 19.75% while the S&P 500 has fallen -1.22% as of 12:07 PM on Monday, Jan 27. KLDO is higher by $1.50 from the previous closing price of $7.61 on volume of 278,823 shares. Over the past year the S&P 500 is higher by 16.57% while KLDO has fallen -39.27%. KLDO lost -$3.85 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Kaleido Biosciences Inc click here.

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium

InvestorsObserver Premium

$ 16.58 $ 8.29 /month
$199 $99.50 billed annually

Related Articles

Sector Update: Health Care

Sector Update: Health Care Stocks Falling as Market Rout Continues

Sector Update: Chipmakers Carrying Tech Stocks to Small Gains

Related Companies